You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 7, 2024

ALVOGEN Company Profile

✉ Email this page to a colleague

« Back to Dashboard

What is the competitive landscape for ALVOGEN, and what generic and branded alternatives to ALVOGEN drugs are available?

ALVOGEN has fifty-seven approved drugs.

There are two tentative approvals on ALVOGEN drugs.

Summary for ALVOGEN

US Patents:	0
Tradenames:	47
Ingredients:	45
NDAs:	57
Patent Litigation for ALVOGEN:	See patent lawsuits for ALVOGEN
PTAB Cases with ALVOGEN as petitioner:	See PTAB cases with ALVOGEN as petitioner

Drugs and US Patents for ALVOGEN

+ Get email alerts for changes to this table

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alvogen	METHYLPHENIDATE HYDROCHLORIDE	methylphenidate hydrochloride	TABLET, EXTENDED RELEASE;ORAL	210818-002	Nov 30, 2018		DISCN	No	No		⤷ Sign Up				⤷ Sign Up
Alvogen	HYDROCODONE BITARTRATE AND ACETAMINOPHEN	acetaminophen; hydrocodone bitartrate	TABLET;ORAL	209958-004	Oct 24, 2018		DISCN	No	No		⤷ Sign Up				⤷ Sign Up
Alvogen	BUPRENORPHINE HYDROCHLORIDE	buprenorphine hydrochloride	FILM;BUCCAL	211594-005	Aug 3, 2021		DISCN	No	No		⤷ Sign Up				⤷ Sign Up
Alvogen	RIVASTIGMINE	rivastigmine	FILM, EXTENDED RELEASE;TRANSDERMAL	204403-001	Sep 3, 2015	AB	RX	No	No		⤷ Sign Up				⤷ Sign Up
Alvogen	HYDROCODONE BITARTRATE AND ACETAMINOPHEN	acetaminophen; hydrocodone bitartrate	TABLET;ORAL	208540-003	Nov 8, 2018		DISCN	No	No		⤷ Sign Up				⤷ Sign Up
Alvogen	HYDROCODONE BITARTRATE	hydrocodone bitartrate	TABLET, EXTENDED RELEASE;ORAL	208269-004	Mar 1, 2021	AB	RX	No	No		⤷ Sign Up				⤷ Sign Up
Alvogen	TAMBOCOR	flecainide acetate	TABLET;ORAL	018830-002	Oct 31, 1985		DISCN	No	No		⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for ALVOGEN

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Alvogen	TAMBOCOR	flecainide acetate	TABLET;ORAL	018830-004	Aug 23, 1988	4,642,384	⤷ Sign Up
Alvogen	TRANDATE	labetalol hydrochloride	TABLET;ORAL	018716-004	Aug 1, 1984	4,012,444	⤷ Sign Up
Alvogen	TRANDATE	labetalol hydrochloride	TABLET;ORAL	018716-001	May 24, 1985	4,066,755	⤷ Sign Up
Alvogen	TAMBOCOR	flecainide acetate	TABLET;ORAL	018830-002	Oct 31, 1985	4,005,209	⤷ Sign Up
Alvogen	SPECTAZOLE	econazole nitrate	CREAM;TOPICAL	018751-001	Dec 23, 1982	3,839,574	⤷ Sign Up
Alvogen	TAMBOCOR	flecainide acetate	TABLET;ORAL	018830-004	Aug 23, 1988	3,800,481	⤷ Sign Up
Alvogen	TRANDATE	labetalol hydrochloride	TABLET;ORAL	018716-003	Aug 1, 1984	4,012,444	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.